Chacko Jacob 4

4 · Oric Pharmaceuticals, Inc. · Filed Dec 17, 2025

Form 4

Period: 2025-12-15

DirectorPRESIDENT AND CEO

Transactions

Exercise/Conversion
Common Stock
2025-12-15+83,666→ 615,085 total
Sale
Common Stock
2025-12-16$9.06/sh−33,374$302,368→ 581,711 total
Exercise/Conversion
Restricted Stock Unit
2025-12-15−22,000→ 0 total
→ Common Stock (22,000 underlying)
Exercise/Conversion
Restricted Stock Unit
2025-12-15−28,333→ 28,334 total
→ Common Stock (28,333 underlying)
Exercise/Conversion
Restricted Stock Unit
2025-12-15−33,333→ 66,667 total
→ Common Stock (33,333 underlying)

Footnotes (6)

[F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.
[F2]Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.
[F3]Represents the weighted average share price of an aggregate total of 33,374 shares sold in the price range of $9.0257 to $9.095 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F4]1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.
[F5]1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.
[F6]1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.

Documents

1 file